Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Authors:
- Rosie Z. YuRYRosie Z. Yu
- André A VanvlietAVAndré A Vanvliet
- 1 January 2009
- journal article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 48 (1) , 39-50
Abstract
Background and objectives Mipomersen sodium (ISIS 301012) is a 20-mer phosphorothioate antisense oligonucleotide that is complementary to human apolipoprotein B-100 (apoB-100) messenger RNA and...Keywords
This publication has 26 references indexed in Scilit:
- Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100Drug Metabolism and Disposition, 2007
- Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein BCirculation, 2006
- Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302)Oligonucleotides, 2006
- Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panelJournal of Internal Medicine, 2006
- Lack of Pharmacokinetic Interaction for ISIS 113715, a 2???-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or RosiglitazoneClinical Pharmacokinetics, 2006
- EzetimibeClinical Pharmacokinetics, 2005
- A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2004
- Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in HumansThe Journal of Clinical Pharmacology, 2004
- Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-αThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Prediction of Furan Pharmacokinetics from Hepatocyte Studies: Comparison of Bioactivation and Hepatic Dosimetry in Rats, Mice, and HumansToxicology and Applied Pharmacology, 1996